Dr. Leonard Sojka who has spent over 25 years with the innovation-driven Merck group explains how Merck is turning its focus to science and technology; his experience on market access; the specificities of the Slovak market; and why Merck is a great company to work for.
2015-16 has been a very busy period for Merck, with a new global CEO, new directives in terms of group offerings, a focus on profitability, growth of existing products, a hastening of R&D, and the development of three new divisions: healthcare, life science, and performance materials. Given your long association with the German group (more than 25 years), what do you see as the key impacts of this new direction in the CEE (Central Eastern Europe) region and on Slovakia?
"In the context of the Central Eastern Europe, Slovak rules are very transparent. Certain industries do lobby our policy-makers but abide by compliance and internal regulations."
